The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines

[1] Bajorin DF(1993)Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study J Clin Oncol 11 598-606

[2] Sarosdy MF(1988)Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines Cancer Res 48 3019-3024

[3] Pfister DG(2005)Steady states and oscillations in the p53/Mdm2 network Cell Cycle 4 488-493

[4] Mazumdar M(1997)Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines Invest New Drugs 15 109-114

[5] Motzer RJ(1990)Treatment of testicular cancer: a new and improved model J Clin Oncol 8 1777-1781

[6] Scher HI(1977)Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer Ann Intern Med 87 293-298

[7] Geller NL(2000)Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF Biochem Pharmacol 60 1305-1313

[8] Fair WR(2002)JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin Biochem Pharmacol 63 1989-1996

[9] Herr H(1994)Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines Anticancer Drugs 5 321-328

[10] Sogani P(2003)MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation EMBO J 22 6365-6377

[1] Bajorin DF(1993)Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study J Clin Oncol 11 598-606

[2] Sarosdy MF(1988)Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines Cancer Res 48 3019-3024

[3] Pfister DG(2005)Steady states and oscillations in the p53/Mdm2 network Cell Cycle 4 488-493

[4] Mazumdar M(1997)Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines Invest New Drugs 15 109-114

[5] Motzer RJ(1990)Treatment of testicular cancer: a new and improved model J Clin Oncol 8 1777-1781

[6] Scher HI(1977)Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer Ann Intern Med 87 293-298

[7] Geller NL(2000)Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF Biochem Pharmacol 60 1305-1313

[8] Fair WR(2002)JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin Biochem Pharmacol 63 1989-1996

[9] Herr H(1994)Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines Anticancer Drugs 5 321-328

[10] Sogani P(2003)MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation EMBO J 22 6365-6377